Bhuvana A. Setty

Dr. Bhuvana Setty, M.D.

Claim this profile

Nationwide Children's Hospital

Studies Soft Tissue Sarcoma
Studies Ewing Sarcoma
10 reported clinical trials
20 drugs studied

Area of expertise

1

Soft Tissue Sarcoma

Bhuvana Setty, M.D. has run 5 trials for Soft Tissue Sarcoma. Some of their research focus areas include:

Stage IV
PAX/FOXO1 fusion positive
SMARCB1 positive
2

Ewing Sarcoma

Bhuvana Setty, M.D. has run 4 trials for Ewing Sarcoma. Some of their research focus areas include:

Stage IV

Affiliated Hospitals

Image of trial facility.

Nationwide Children's Hospital

Image of trial facility.

The Research Institute At Nationwide Children's Hospital

Clinical Trials Bhuvana Setty, M.D. is currently running

Image of trial facility.

NK Cells + Chemotherapy

for Sarcoma

The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people with childhood sarcomas that have relapsed or not responded to prior therapies. The goals of this study are: * To determine the safety and efficacy of the addition of adoptive transfer of universal donor, TGFβ imprinted (TGFβi), expanded NK cells to the pediatric sarcoma salvage chemotherapeutic regimen gemcitabine/docetaxel (GEM/DOX) for treatment of relapsed and refractory pediatric sarcomas To determine the 6-month progression free survival achieved with this treatment in patients within cohorts of relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma. * To identify toxicities related to treatment with GEM/DOX + TGFβi expanded NK cells Participants will receive study drugs that include chemotherapy and NK cells in cycles; each cycle is 21 days long and you can receive up to 8 cycles. * Gemcitabine (GEM): via IV on Days 1 and 8 * Docetaxel (DOX): via IV on Day 8 * Prophylactic dexamethasone: Day 7-9 to prevent fluid retention and hypersensitivity reaction * Peg-filgrastim (PEG-GCSF) or biosimilar: Day 9 to help your white blood cell recover and allow more chemotherapy to be given * TGFβi NK cells: via IV on Day 12

Recruiting

1 award

Phase 1 & 2

Image of trial facility.

Liquid Biopsy

for Bone Cancer

This trial is testing a blood test that looks for small pieces of tumor DNA in patients with Ewing sarcoma or osteosarcoma. The goal is to see if this test can help predict if the cancer will return after treatment. A group of patients will participate to help researchers understand how useful this test can be.

Recruiting

1 award

N/A

15 criteria

More about Bhuvana Setty, M.D.

Clinical Trial Related

4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Bhuvana Setty, M.D. has experience with

  • Gemcitabine
  • Cyclophosphamide
  • Vincristine
  • Docetaxel
  • TGFβi Expanded NK Cells
  • Vinorelbine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Bhuvana Setty, M.D. specialize in?

Is Bhuvana Setty, M.D. currently recruiting for clinical trials?

Are there any treatments that Bhuvana Setty, M.D. has studied deeply?

What is the best way to schedule an appointment with Bhuvana Setty, M.D.?

What is the office address of Bhuvana Setty, M.D.?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security